Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders

被引:102
作者
Ketter, TA
Manji, HK
Post, RM
机构
[1] Stanford Univ, Dept Psychiat & Behav Sci, Bipolar Disorders Clin, Stanford, CA 94305 USA
[2] US Dept HHS, NIMH, Bethesda, MD USA
关键词
D O I
10.1097/01.jcp.0000088915.02635.e8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Based on the mood-stabilizing properties of carbamazepine and valproate, new anticonvulsants have been explored for use in bipolar disorders. One such agent lamotrigine, has recently been approved as a maintenance treatment for bipolar I disorder, and has a novel clinical profile in that it may "stabilize mood from below," as it appears to maximally impact depressive symptoms in bipolar disorders. In this paper, we review the mechanisms of action of lamotrigine in an effort to understand the basis of its distinctive clinical use in the management of bipolar disorders as well as its diverse antiseizure effects. We consider lamotrigine mechanisms, emphasizing commonalities and dissociations among actions of lamotrigine, older mood stabilizers, and other anticonvulsants. Although ion channel effects, especially sodium channel blockade, may importantly contribute to antiseizure effects, such actions may be less central to lamotrigine thymoleptic effects. Antiglutamatergic and neuroprotective actions are important candidate mechanisms for lamotrigine psychotropic effects. Lamotrigine has a variable profile in kindling and contingent tolerance experiments and does not appear to have robust gamma-aminobutyric acid or monoaminergic actions. Lamotrigine intracellular signaling effects warrant investigation. Although lamotrigine mechanisms overlap those of other mood-stabilizing anticonvulsants, important dissociations suggest candidate mechanisms, which could contribute to lamotrigine's distinctive psychotropic profile.
引用
收藏
页码:484 / 495
页数:12
相关论文
共 128 条
[1]   Attenuation of the neuropsychiatric effects of ketamine with lamotrigine -: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists [J].
Anand, A ;
Charney, DS ;
Oren, DA ;
Berman, RM ;
Hu, XS ;
Cappiello, A ;
Krystal, JH .
ARCHIVES OF GENERAL PSYCHIATRY, 2000, 57 (03) :270-276
[2]   A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania [J].
Bebchuk, JM ;
Arfken, CL ;
Dolan-Manji, S ;
Murphy, J ;
Hasanat, K ;
Manji, HK .
ARCHIVES OF GENERAL PSYCHIATRY, 2000, 57 (01) :95-97
[3]   NEW ANTIEPILEPTIC DRUGS [J].
BENETELLO, P .
PHARMACOLOGICAL RESEARCH, 1995, 31 (3-4) :155-162
[4]  
Bergen Donna, 1994, Epilepsia, V35, P163
[5]  
BERNASCONI R, 1979, N-S ARCH PHARMACOL, V307, pR63
[6]  
Bernasconi R., 1984, ANTICONVULSANTS AFFE, P14
[7]  
Bernasconi R., 1982, BASIC MECHANISMS ACT, P183
[8]   Effects of four antiepileptic drugs on sleep and waking in the rat under both light and dark phases [J].
Bertorelli, R ;
Ferri, N ;
Adami, M ;
Ongini, E .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1996, 53 (03) :559-565
[9]   HUMAN SAFETY OF LAMOTRIGINE [J].
BETTS, T ;
GOODWIN, G ;
WITHERS, RM ;
YUEN, AWC .
EPILEPSIA, 1991, 32 :S17-S21
[10]   Emergent properties of networks of biological signaling pathways [J].
Bhalla, US ;
Iyengar, R .
SCIENCE, 1999, 283 (5400) :381-387